Table of Contents

company-logo

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Aridis Pharmaceuticals Dividend Announcement

• Aridis Pharmaceuticals does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Aridis Pharmaceuticals dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Aridis Pharmaceuticals Dividend History

Aridis Pharmaceuticals Dividend Yield

Aridis Pharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Aridis Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

Aridis Pharmaceuticals Financial Ratios

P/E ratio0.00
PEG ratio-0.00
P/B ratio-0.00
ROE-62.63%
Payout ratio0.00%
Current ratio0.37
Quick ratio0.40
Cash Ratio0.00

Aridis Pharmaceuticals Dividend FAQ

Does Aridis Pharmaceuticals stock pay dividends?
Aridis Pharmaceuticals does not currently pay dividends to its shareholders.
Has Aridis Pharmaceuticals ever paid a dividend?
No, Aridis Pharmaceuticals has no a history of paying dividends to its shareholders. Aridis Pharmaceuticals is not known for its dividend payments.
Why doesn't Aridis Pharmaceuticals pay dividends?
There are several potential reasons why Aridis Pharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Aridis Pharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Aridis Pharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Aridis Pharmaceuticals a dividend aristocrat?
Aridis Pharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Aridis Pharmaceuticals a dividend king?
Aridis Pharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Aridis Pharmaceuticals a dividend stock?
No, Aridis Pharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Aridis Pharmaceuticals stocks?
To buy Aridis Pharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Aridis Pharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.